Developing New Hope
Developing and testing new therapeutic agents is costly and time-consuming, but these experimental agents offer the most promise for preventing, treating and ultimately curing cancer. Pelotonia funds support two important cancer drug development projects at Ohio State: an early-phase clinical trial on the safety of a novel anticancer vaccine to prevent several types of solid tumors, and a phase II clinical trial that will supplement an ongoing study of a new drug against chronic lymphocytic leukemia (CLL).
The vaccine trial, led by overall chair Pravin Kaumaya, PhD, and clinical principal investigator Tanios Bekaii-Saab, MD, opened at The James last July; six patients have been treated to date. The CLL drug discovery trial, led by John C. Byrd, MD, involves an agent called PCI-32765 in combination with a monoclonal antibody called Ofatumumab. An interim analysis of the ongoing phase II study indicated that PCI-32765 is highly active and well-tolerated in CLL patients undergoing initial treatment or who have relapsed and are resistant to other therapy.
Providing Tools for Discovery
Many cancer researchers could not function without sophisticated equipment that helps them with such critical procedures as sequencing genes, sorting and characterizing individual cells, bioimaging, microscopy and data collection, to name just a few. Funding from the Pelotonia rides has helped bring nearly $2 million worth of the world’s most advanced technology to the OSUCCC – James to support the needs of more than 200 cancer researchers. Maintaining state-of-the-art technology is critical for our scientists to remain competitive in the fight against cancer.
- With its many lasers, the Special BD FacsAria analytical cytometer brings new high-speed capabilities for sorting normal and cancer cells for genomic characterization.
- The SOLiD™ System is a highly accurate, massively parallel, gene-sequencing platform that supports a range of applications.
- The HiSeq™ 2000 Sequencer escalates sequencing throughput to enable researchers to sequence deeply, broadly and economically, accelerating the path to personalized medicine.